SKIN.SW stock rose 9.85% to CHF35.70 at market close on 05 Mar 2026, making it one of today’s high volume movers on the SIX exchange in Switzerland. Volume finished at 2,756.00 versus an average of 1,818.00, a 1.52x pickup that helped lift the price from an open of CHF32.00 to a day high of CHF36.00. There is no scheduled earnings announcement today, so the move appears driven by intraday flows and clinical or sector chatter rather than a company release. We contextualise the jump, valuation, technicals and risk for investors watching SKIN.SW stock.

SKIN.SW stock: price action and volume

Cassiopea S.p.A. (SKIN.SW) closed at CHF35.70, up 9.85%, with 2,756.00 shares traded, compared with an average daily volume of 1,818.00. The relative volume of 1.52 shows unusually strong participation for a SIX-listed biotech name and explains the stock’s inclusion among high volume movers.

The move lifted the share price above the 50-day average of CHF34.37 while it remains below the 200-day average of CHF37.22, signalling a short-term bullish tilt inside a longer-term consolidation range between the year low CHF25.70 and year high CHF53.00.

SKIN.SW stock fundamentals and valuation

Cassiopea is a clinical-stage dermatology biotech; revenue per share is CHF0.00 and EPS is CHF-1.27, reflecting ongoing R&D and negative profitability. The trailing P/E prints -28.13 and price-to-book is 26.22, indicating valuation is driven by clinical upside rather than current earnings.

Balance-sheet metrics are mixed: cash per share is CHF0.25 and current ratio is 1.98, giving operating runway some support. Investors should weigh biotech upside in products such as Winlevi and Breezula against persistent negative earnings and high valuation multiples.

SKIN.SW stock technicals and trading signals

Technically, SKIN.SW stock cleared short-term resistance at the 50-day moving average CHF34.37 on higher volume, a positive intraday confirmation for momentum traders. The day range was CHF32.00 to CHF36.00, and the RSI and short-term momentum are showing improvement, supporting a potential continuation to the 200-day average.

Key technical risks include the nearby 200-day average at CHF37.22 and the year high at CHF53.00, which may act as resistance. Stop-loss placement near the intraday low CHF32.00 would limit downside for tactical trades.

SKIN.SW stock: sector context and liquidity

SKIN.SW trades on the SIX in Switzerland and sits in the Healthcare / Biotechnology industry, where the sector 1-day performance was -1.22% today. Cassiopea’s outperformance versus the sector highlights stock-specific flows rather than broad healthcare strength.

Liquidity is modest: average volume 1,818.00 means large blocks can move the price. Traders should account for wider spreads and lower market depth relative to large-cap healthcare names on the Swiss market.

Meyka AI rates SKIN.SW with a score out of 100

Meyka AI rates SKIN.SW with a score of 62.67 / 100 and assigns a B (HOLD) suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI, an AI-powered market analysis platform, uses this composite to flag stocks with balanced risk-reward. Disclaimer: these grades are informational and not personal financial advice.

Meyka AI’s forecast and scenarios for SKIN.SW stock

Meyka AI’s forecast model projects a near-term target of CHF42.00, implying an upside of 17.65% versus the close at CHF35.70. A conservative downside scenario at CHF31.00 implies a drop of -13.18%.

Forecasts are model-based projections and not guarantees. With EPS negative and elevated PB, catalysts such as clinical trial updates or licensing news will drive the next major moves.

Final Thoughts

Key takeaways on SKIN.SW stock: the share closed at CHF35.70 on 05 Mar 2026 after a 9.85% gain and 2,756.00 shares traded, marking it as a high volume mover on the SIX in Switzerland. Short-term technicals improved after a decisive break above the 50-day average CHF34.37, but the stock remains below the 200-day average CHF37.22, so momentum needs confirmation. Fundamentals show negative EPS CHF-1.27 and a high price-to-book 26.22, reflecting clinical-stage risk and premium valuation. Meyka AI’s model projects CHF42.00 (implied upside 17.65%) while a conservative downside case sits at CHF31.00 (implied –13.18%). Given limited liquidity and no immediate earnings catalyst, our B/HOLD grade suggests monitoring clinical announcements or volume-confirmed breakouts before adding exposure. For company filings and product detail, see the Cassiopea site and our internal coverage at Meyka SKIN.SW page. Forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.